Argenx Shares Fall on Dropped Sjögrens Drug Trial
Argenx shares dropped 16 percent after the company discontinued a late-stage study of its Vyvgart drug for Sjögrens disease. An independent committee recommended stopping the trial because it was unlikely to meet its primary endpoint.
Xurve View
Insights:
Xurve View
ARGENX SE - ADR halted a late-stage study of its efgartigimod treatment for Sjögren's disease on Thursday morning after an interim review. The trial termination triggered a 16% share price drop, marking the company's steepest one-day decline in almost three years. European investors rushed to reprice the stock as a key rheumatology expansion avenue closed.
